Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Dexedrine Adds Black Box On Cardiovascular Events

This article was originally published in The Pink Sheet Daily

Executive Summary

ADHD product also adds class warnings on psychiatric events, seizures and visual disturbance.

You may also be interested in...



Novartis’ Ritalin LA Faces Patent Challenge

Patents relate to controlled-release dosing forms.

Novartis’ Ritalin LA Faces Patent Challenge

Patents relate to controlled-release dosing forms.

Shire’s New ADHD Drug Coming Into Focus

Connexyn (guanfacine extended release) could be approved in mid-2007 and would be the second non-stimulant in category.

Related Content

Topics

UsernamePublicRestriction

Register

PS064712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel